press releases

Lysogene Announces Filing of 2020 Universal Registration Document
Lysogene Announces Filing of 2020 Universal Registration Document 150 150 Lysogene

Paris, France — 13 April 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…

Lysogene announces its financial calendar for 2021
Lysogene announces its financial calendar for 2021 150 150 Lysogene

Paris, France — 25 January 2021 at 08:00am — Lysogene (FR0013233475 – LYS), a phase…

Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux
Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux 150 150 Lysogene

Paris, France — 15 January 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…

Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis
Lysogene Receives MHRA and Research Ethics Committee Approvals to Initiate the Gene Therapy Clinical Trial in the UK with LYS-GM101 for the Treatment of GM1 Gangliosidosis 150 150 Lysogene

LYS-GM101 is Lysogene’s second CNS gene therapy program to enter clinicTrial enrollment expected to begin…

Lysogene Reports Positive Biomarker data with LYS-SAF302
Lysogene Reports Positive Biomarker data with LYS-SAF302 150 150 Lysogene

Decrease in heparan sulfate concentration in cerebrospinal fluidDecrease in GM2 and GM3 ganglioside in cerebrospinal…

Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
Lysogene Reports First Half 2020 Financial Results and Provides Operational Update 150 150 Lysogene

Cash position of €23.8m as of 30 June 2020 strengthened by a €7.7m capital increase ledby OrbiMed and Sarepta, extending cash runway to Q4 2021

Lysogene: First Half 2020 Business Update
Lysogene: First Half 2020 Business Update 150 150 Lysogene

Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…

Lysogene announces a research collaboration with the Weizmann Institute of Science
Lysogene announces a research collaboration with the Weizmann Institute of Science 150 150 Lysogene

Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…

LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting
LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting 150 150 Lysogene

Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…

Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA 150 150 Lysogene

Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top